Committed to address
AstriVax NV is a privately held Belgian company founded in 2022 based on vaccine technology developed at the Rega Institute (KU Leuven). AstriVax has secured a seed round of € 30 million with a strong investor syndicate to continue building the vaccine technology platform and bring the first vaccines into clinical development. The company is located in Haasrode (Leuven).
First in class Plug & Play vaccine platform.
Patented DNA-based technology that launches self-amplifying live attenuated viruses, resulting in polyfunctional and vigorous nature of the immune response.
Wide range of potential use – prophylactic and therapeutic vaccines.